FZX Stock Overview
A healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ainos, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.63 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$2.49 |
| Beta | 1.45 |
| 11 Month Change | 0% |
| 3 Month Change | 1.20% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1,123.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| FZX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | 0.8% |
| 1Y | n/a | -18.3% | 8.6% |
Return vs Industry: Insufficient data to determine how FZX performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how FZX performed against the German Market.
Price Volatility
| FZX volatility | |
|---|---|
| FZX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FZX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FZX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 43 | Chun-Hsien Tsai | www.ainos.com |
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products.
Ainos, Inc. Fundamentals Summary
| FZX fundamental statistics | |
|---|---|
| Market cap | €8.94m |
| Earnings (TTM) | -€12.61m |
| Revenue (TTM) | €111.78k |
80.0x
P/S Ratio-0.7x
P/E RatioIs FZX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FZX income statement (TTM) | |
|---|---|
| Revenue | US$122.11k |
| Cost of Revenue | US$375.85k |
| Gross Profit | -US$253.73k |
| Other Expenses | US$13.52m |
| Earnings | -US$13.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | -207.79% |
| Net Profit Margin | -11,276.98% |
| Debt/Equity Ratio | 23.3% |
How did FZX perform over the long term?
See historical performance and comparison